HLF

Herbalife is a textbook deep-value setup: at $12.79 the stock trades at 5.8x FY2025 diluted EPS of $2.20 and 0.3x sales, with a market cap ($1.32B) smaller than annual operating cash flow would suggest. The cash engine is the bull case — FY2025 operating cash flow rose 16.8% to $333M against just $80.4M of capex (itself down 34%), leaving roughly $253M of free cash flow, a ~19% FCF yield. Gross margin is a fat 77.9% and operating income jumped 24.6% to $481M (9.5% operating margin), evidence that the restructuring and localized pricing actions management cites in the MD&A are taking hold on the cost line.

The problem is what sits beneath that cash flow. The top line is in a multi-year drift — revenue has fallen from $5.80B (FY2021) to $5.04B (FY2025), and FY2025's +0.9% was barely positive and helped by pricing, not volume. Net income (-10.2%) and EPS (-12.0%) both declined despite the operating-income jump, and the balance sheet is genuinely stressed: stockholders' equity is negative (-$515M), retained earnings are -$580M, and long-term debt of $1.97B dwarfs $353M of cash (down 15%). Net debt sits near 2.7x EBITDA (operating income $481M + D&A $121M ≈ $602M) — serviceable given the FCF, but it leaves no margin for a demand shock.